Tolterodine detailed information

Tolterodine detailed information

File:Tolterodine.png
Clinical data
ATC code	G04BD07 (WHO)
Pharmacokinetic data
Bioavailability	77%
Protein binding	Approximately 96.3%.
Elimination half-life	1.9-3.7 hours
Identifiers
IUPAC name 2-[3-[bis(1-methylethyl)amino]- 1-phenyl-propyl]-4-methyl-phenol
CAS Number	124937-51-5
PubChem CID	60774
DrugBank	APRD00146
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C22H31NO
Molar mass	325.488 g/mol

Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. It is sold under the trade name Detrol.

Pharmacology

Tolterodine acts on M2 and M3 subtypes of muscarinic receptors whereas most antimuscarinic treatments for overactive bladder only act on M3 receptors making them more selective.

Tolterodine, although it acts on two types of receptors, has fewer side effects than other antimuscarinics eg. oxybutynin (which is selective for M3 only) as tolterodine targets the bladder more than other areas of the body. This means that less drug needs to be given daily (due to efficient targeting of the bladder) and so there are fewer side effects.

Side effects

Known Side Effects:

• Hyposalivation (Dry mouth)
• Decreased gastric motility (Upset stomach)
• Headache
• Constipation
• Dry eyes
• Sleepiness

Reports of Patients’ Experiences Since Detrol Became Available:

The following reactions have been reported in patients who have taken Detrol since it has become available:

• Allergic reactions including swelling
• Rapid heartbeat or abnormal heartbeat
• Accumulation of fluid in the arms and legs
• Hallucinations

Contraindications Not to be used in patients with Myasthenia Gravis and Angle Closure Glaucoma

External links

• Detrol - FDA factsheet
• Tolterodine
• Tolterodine (patient information)

Template:Pharma-stub Template:WikiDoc Sources